A Controlled Trial of Dexamethasone in Preterm Infants at High Risk for Bronchopulmonary Dysplasia

Authors:
  • DDDiane B. D'EUgenio
    Diane B. D'EUgenio
  • SGSteven J. Gross
    Steven J. Gross
Publisher website
Google Scholar
Abstract
We evaluated the use of dexamethasone in preterm infants to decrease morbidity associated with bronchopulmonary dysplasia in a randomized, double-blind, placebo-controlled trial. Thirty-six preterm infants (birth weight, ≤250 g and gestational age, ≤30 weeks) who were dependent on oxygen and mechanical ventilation at two weeks of age received a 42-day course of dexamethasone (n=13), an 18-day course of dexamethasone (n=12), or saline placebo (n=11). The starting dose of dexamethasone was 0.5 mg per kilogram of body weight per day, and it was progressively lowered during the period of administration.

This publication has 13 references indexed in Scilit: